{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:23:34Z","timestamp":1790915014320,"version":"4.1.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","funder":[{"name":"Mayo Translational Polycystic Kidney Disease Center","award":["DK090728"],"award-info":[{"award-number":["DK090728"]}]},{"name":"Pirnie Family Foundation"},{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"publisher","award":["UL1 RR024150"],"award-info":[{"award-number":["UL1 RR024150"]}],"id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007048","name":"Mayo Foundation for Medical Education and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007048","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Mayo CTSA Center"},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","award":["CSOM230XUS30T"],"award-info":[{"award-number":["CSOM230XUS30T"]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK24031"],"award-info":[{"award-number":["DK24031"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR002377"],"award-info":[{"award-number":["UL1 TR002377"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJASN"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background and objectives<\/jats:title>\n                    <jats:p>We assessed safety and efficacy of another somatostatin receptor analog, pasireotide long-acting release, in severe polycystic liver disease and autosomal dominant polycystic kidney disease. Pasireotide long-acting release, with its broader binding profile and higher affinity to known somatostatin receptors, has potential for greater efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, setting, participants, &amp; measurements<\/jats:title>\n                    <jats:p>Individuals with severe polycystic liver disease were assigned in a 2:1 ratio in a 1-year, double-blind, randomized trial to receive pasireotide long-acting release or placebo. Primary outcome was change in total liver volume; secondary outcomes were change in total kidney volume, eGFR, and quality of life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 48 subjects randomized, 41 completed total liver volume measurements (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =29 pasireotide long-acting release and\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =12 placebo). From baseline, there were \u221299\u00b1189 ml\/m absolute and \u22123%\u00b17% change in annualized change in height-adjusted total liver volume (from 2582\u00b11381 to 2479\u00b11317 ml\/m) in the pasireotide long-acting release group compared with 136\u00b1117 ml\/m absolute and 6%\u00b17% increase (from 2387\u00b1759 to 2533\u00b1770 ml\/m) in placebo (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001 for both). Total kidney volumes decreased by \u221212\u00b134 ml\/m and \u22121%\u00b14% in pasireotide long-acting release compared with 21\u00b121 ml\/m and 4%\u00b15% increase in the placebo group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.05 for both). Changes in eGFR were similar between groups. Among the\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      =48 randomized, adverse events included hyperglycemia (26 of 33 [79%] in pasireotide long-acting release versus four of 15 [27%] in the placebo group;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001), and among the 47 without diabetes at baseline, 19 of 32 (59%) in the pasireotide long-acting release group versus one of 15 (7%) in the placebo group developed diabetes (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Another somatostatin analog, pasireotide long-acting release, slowed progressive increase in both total liver volume\/total kidney volume growth rates without affecting GFR decline. Participants experienced higher frequency of adverse events (hyperglycemia and diabetes).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial registry name and registration number<\/jats:title>\n                    <jats:p>Pasireotide LAR in Severe Polycystic Liver Disease, NCT01670110<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Podcast<\/jats:title>\n                    <jats:p>This article contains a podcast at https:\/\/www.asn-online.org\/media\/podcast\/CJASN\/2020_08_28_CJN13661119.mp3<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2215\/cjn.13661119","type":"journal-article","created":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T15:30:12Z","timestamp":1598369412000},"page":"1267-1278","source":"Crossref","is-referenced-by-count":40,"title":["Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement"],"prefix":"10.2215","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct01670110","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3031-8522","authenticated-orcid":false,"given":"Marie C.","family":"Hogan","sequence":"first","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Chamberlin","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa E.","family":"Vaughan","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela L.","family":"Waits","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly","family":"Banks","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Leistikow","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"Oftsie","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuck","family":"Madsen","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Edwards","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, Minnesota"},{"name":"Biomedical Imaging Research Core Facility, PKD Translational Research Center, Mayo Clinic College of Medicine, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Glockner","sequence":"additional","affiliation":[{"name":"Department of Radiology, Mayo Clinic College of Medicine, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter K.","family":"Kremers","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Harris","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas F.","family":"LaRusso","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4963-1132","authenticated-orcid":false,"given":"Vicente E.","family":"Torres","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana V.","family":"Masyuk","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,8,25]]},"reference":[{"key":"B1-20230813","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2215\/CJN.00080605","article-title":"Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: The consortium for radiologic imaging studies of polycystic kidney disease cohort","volume":"1","author":"Bae","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"B2-20230813","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cgh.2014.07.051","article-title":"Liver involvement in early autosomal-dominant polycystic kidney disease","volume":"13","author":"Hogan","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol"},{"key":"B3-20230813","first-page":"226","article-title":"Clinical predictors of escalating care in hepatic and renal cyst infection in autosomal dominant polycystic kidney and liver disease","volume":"76","author":"Lantinga","year":"2018","journal-title":"Neth J Med"},{"key":"B4-20230813","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/2050640617705577","article-title":"Impact of liver volume on polycystic liver disease-related symptoms and quality of life","volume":"6","author":"Neijenhuis","year":"2018","journal-title":"United European Gastroenterol J"},{"key":"B5-20230813","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12882-016-0434-0","article-title":"Total kidney and liver volume is a major risk factor for malnutrition in ambulatory patients with autosomal dominant polycystic kidney disease","volume":"18","author":"Ryu","year":"2017","journal-title":"BMC Nephrol"},{"key":"B6-20230813","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1681\/ASN.2017010084","article-title":"Biliary tract and liver complications in polycystic kidney disease","volume":"28","author":"Judge","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B7-20230813","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.mayocpiqo.2019.03.004","article-title":"Bacterial cholangitis in autosomal dominant polycystic kidney and liver disease","volume":"3","author":"Martin","year":"2019","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"B8-20230813","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1111\/liv.13041","article-title":"Combined liver-kidney transplantation for polycystic liver and kidney disease: Analysis from the united network for organ sharing dataset","volume":"36","author":"Coquillard","year":"2016","journal-title":"Liver Int"},{"key":"B9-20230813","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S1665-2681(19)31637-0","article-title":"Clinical outcomes of liver transplantation for polycystic liver disease: A single center experience","volume":"9","author":"Chandok","year":"2010","journal-title":"Ann Hepatol"},{"key":"B10-20230813","first-page":"27","article-title":"Improving outcomes of liver transplantation for polycystic disease in MELD era","volume":"4","author":"Saidi","year":"2013","journal-title":"Int J Organ Transplant Med"},{"key":"B11-20230813","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrgastro.2014.155","article-title":"Polycystic liver diseases: Advanced insights into the molecular mechanisms","volume":"11","author":"Perugorria","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B12-20230813","doi-asserted-by":"crossref","first-page":"950","DOI":"10.2174\/1389450116666150427161743","article-title":"Therapeutic targets in polycystic liver disease","volume":"18","author":"Masyuk","year":"2017","journal-title":"Curr Drug Targets"},{"key":"B13-20230813","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.cgh.2016.03.008","article-title":"Polycystic liver disease: The benefits of targeting cAMP","volume":"14","author":"Larusso","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B14-20230813","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1002\/hep.22636","article-title":"The cAMP effectors Epac and protein kinase a (PKA) are involved in the hepatic cystogenesis of an animal model of autosomal recessive polycystic kidney disease (ARPKD)","volume":"49","author":"Banales","year":"2009","journal-title":"Hepatology"},{"key":"B15-20230813","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1111\/j.1523-1755.2004.00953.x","article-title":"Expression of somatostatin in the adult and developing mouse kidney","volume":"66","author":"Bates","year":"2004","journal-title":"Kidney Int"},{"key":"B16-20230813","doi-asserted-by":"crossref","first-page":"F457","DOI":"10.1152\/ajprenal.2001.280.3.F457","article-title":"Segmental expression of somatostatin receptor subtypes sst(1) and sst(2) in tubules and glomeruli of human kidney","volume":"280","author":"Balster","year":"2001","journal-title":"Am J Physiol Renal Physiol"},{"key":"B17-20230813","first-page":"1323","article-title":"Human kidney as target for somatostatin: High affinity receptors in tubules and vasa recta","volume":"77","author":"Reubi","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"B18-20230813","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1053\/j.gastro.2006.12.039","article-title":"Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3\u2032,5\u2032-cyclic monophosphate","volume":"132","author":"Masyuk","year":"2007","journal-title":"Gastroenterology"},{"key":"B19-20230813","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/hep.26140","article-title":"Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases","volume":"58","author":"Masyuk","year":"2013","journal-title":"Hepatology"},{"key":"B21-20230813","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease","volume":"21","author":"Hogan","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B22-20230813","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2215\/CJN.05380709","article-title":"Reducing polycystic liver volume in ADPKD: Effects of somatostatin analogue octreotide","volume":"5","author":"Caroli","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B23-20230813","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/MOG.0b013e328343433f","article-title":"Somatostatin analogues for treatment of polycystic liver disease","volume":"27","author":"Gevers","year":"2011","journal-title":"Curr Opin Gastroenterol"},{"key":"B24-20230813","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1093\/ndt\/gfs152","article-title":"Somatostatin analog therapy for severe polycystic liver disease: Results after 2 years","volume":"27","author":"Hogan","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B25-20230813","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2019.04.018","article-title":"Lanreotide reduces liver growth in patients with autosomal dominant polycystic liver and kidney disease","volume":"157","author":"van Aerts","year":"2019","journal-title":"Gastroenterology"},{"key":"B26-20230813","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.mayocp.2015.05.011","article-title":"Efficacy of 4 years of octreotide long-acting release therapy in patients with severe polycystic liver disease","volume":"90","author":"Hogan","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"B27-20230813","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cgh.2015.12.049","article-title":"Long-term effects of octreotide on liver volume in patients with polycystic kidney and liver disease","volume":"14","author":"Pisani","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B28-20230813","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/0092-8674(94)90137-6","article-title":"The polycystic kidney disease 1 gene encodes a 14 kb transcript and lies within a duplicated region on chromosome 16. The European Polycystic Kidney Disease Consortium [published correction appears in Cell 78: 725, 1994]","volume":"77","year":"1994","journal-title":"Cell"},{"key":"B29-20230813","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/ng0695-151","article-title":"The polycystic kidney disease 1 (PKD1) gene encodes a novel protein with multiple cell recognition domains","volume":"10","author":"Hughes","year":"1995","journal-title":"Nat Genet"},{"key":"B30-20230813","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ajhg.2016.05.004","article-title":"Mutations in GANAB, encoding the glucosidase II\u03b1 subunit, cause autosomal-dominant polycystic kidney and liver disease","volume":"98","author":"Porath","year":"2016","journal-title":"Am J Hum Genet"},{"key":"B31-20230813","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.272.5266.1339","article-title":"PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein","volume":"272","author":"Mochizuki","year":"1996","journal-title":"Science"},{"key":"B32-20230813","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1086\/316904","article-title":"Identification of a locus for autosomal dominant polycystic liver disease, on chromosome 19p13.2-13.1","volume":"67","author":"Reynolds","year":"2000","journal-title":"Am J Hum Genet"},{"key":"B33-20230813","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ajhg.2018.03.013","article-title":"Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease","volume":"102","author":"Cornec-Le Gall","year":"2018","journal-title":"Am J Hum Genet"},{"key":"B34-20230813","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ajmg.a.30851","article-title":"CDG-IL: An infant with a novel mutation in the ALG9 gene and additional phenotypic features","volume":"136","author":"Weinstein","year":"2005","journal-title":"Am J Med Genet A"},{"key":"B35-20230813","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ymgmr.2017.08.004","article-title":"ALG9-CDG: New clinical case and review of the literature","volume":"13","author":"Davis","year":"2017","journal-title":"Mol Genet Metab Rep"},{"key":"B36-20230813","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1681\/ASN.2019030298","article-title":"ALG9 mutation carriers develop kidney and liver cysts","volume":"30","author":"Besse","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"B37-20230813","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1086\/368295","article-title":"Mutations in PRKCSH cause isolated autosomal dominant polycystic liver disease","volume":"72","author":"Li","year":"2003","journal-title":"Am J Hum Genet"},{"key":"B38-20230813","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ng1104","article-title":"Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease","volume":"33","author":"Drenth","year":"2003","journal-title":"Nat Genet"},{"key":"B39-20230813","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/ng1357","article-title":"Mutations in SEC63 cause autosomal dominant polycystic liver disease","volume":"36","author":"Davila","year":"2004","journal-title":"Nat Genet"},{"key":"B40-20230813","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1073\/pnas.1309438111","article-title":"Whole-exome sequencing reveals LRP5 mutations and canonical Wnt signaling associated with hepatic cystogenesis","volume":"111","author":"Cnossen","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B41-20230813","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1172\/JCI96729","article-title":"Isolated polycystic liver disease genes define effectors of polycystin-1 function. [published correction appears in J Clin Invest 127: 1772\u20131785, 2017]","volume":"127","author":"Besse","year":"2017","journal-title":"J Clin Invest"},{"key":"B42-20230813","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1681\/ASN.2013040398","article-title":"Strategies targeting cAMP signaling in the treatment of polycystic kidney disease","volume":"25","author":"Torres","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"B44-20230813","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1001\/jama.2018.15870","article-title":"Effect of lanreotide on kidney function in patients with autosomal dominant polycystic kidney disease: The DIPAK 1 randomized clinical trial","volume":"320","author":"Meijer","year":"2018","journal-title":"JAMA"},{"key":"B45-20230813","doi-asserted-by":"crossref","first-page":"e1002777","DOI":"10.1371\/journal.pmed.1002777","article-title":"Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial","volume":"16","author":"Perico","year":"2019","journal-title":"PLoS Med"},{"key":"B46-20230813","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/hep.28545","article-title":"Development and validation of a disease-specific questionnaire to assess patient-reported symptoms in polycystic liver disease","volume":"64","author":"Neijenhuis","year":"2016","journal-title":"Hepatology"},{"key":"B47-20230813","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1210\/jc.2013-1771","article-title":"Hyperglycemia associated with pasireotide: Results from a mechanistic study in healthy volunteers","volume":"98","author":"Henry","year":"2013","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.13661119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:39:58Z","timestamp":1786369198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2215\/CJN.13661119"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2020,8,25]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.13661119","relation":{},"ISSN":["1555-9041","1555-905X"],"issn-type":[{"value":"1555-9041","type":"print"},{"value":"1555-905X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,25]]}}}